News & Views
Latest News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda enters license agreement with University of Goettingen
Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates
Licensing agreement with LegoChem Biosciences
LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
LCB and Iksuda Enter into a Multi-Target Research Collaboration
LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
Forging stable relationships for Antibody-Drug Conjugates
DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.
Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer
Sign up for more news
Thank you